Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biotage AB (BITGF)
OTHER OTC:BITGF
Holding BITGF?
Track your performance easily
Earnings Data
Report Date
Feb 19, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.14Last Year’s EPS
0.17Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 07, 2019
|% Change Since: -27.29%
|Next Earnings Date:Nov 06, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and performance in the Astrea business and recurring revenues, yet faced challenges in meeting demand in the peptide segment and significant downturns in the China market and small molecules segment.Company Guidance
During the Q1 2024 earnings call for Biotage (BIOT.ST), key financial metrics were highlighted, showcasing a strong quarter with SEK 480 million in revenue, marking a 33% growth over the previous year. The gross margin improved to 63.1%, up by 2.2 percentage points, and the company achieved an adjusted EBITDA of SEK 126 million, reflecting a 28% increase. Recurring revenue reached 72% of total revenue, with SEK 346 million, significantly rising from 67% the previous year, largely driven by Astrea, which experienced a remarkable 78% growth. Despite challenges in fulfilling peptide business demand, which led to a missed opportunity for additional growth, the company remains optimistic about future capacity expansions. Additionally, Biologics & Advanced Therapeutics now contribute to 30% of total revenue, with a notable 78% revenue increase from Astrea. The company also reported an adjusted cash flow from operations of SEK 171 million and concluded the quarter with SEK 683 million in gross cash and SEK 426 million in net cash. Looking ahead, Biotage anticipates ongoing growth and plans to enhance manufacturing capacity to meet rising demands in the peptide sector.Strong Revenue Growth
The company reported a top line of SEK 480 million, representing a 33% growth over last year, with a gross margin increase to 63.1%.
Astrea Business Performance
Astrea business grew by 78% compared to Q1 2023, contributing significantly to the biologics and advanced therapeutics segment, which now accounts for 30% of total revenue.
High Recurring Revenue
Recurring revenue increased to 72% of total sales, up from 67% in the previous year.
Cash Conversion and EBITDA
The company converted SEK 171 million in cash and reported an adjusted EBITDA of SEK 126 million, up 28% from the previous year.
---
BITGF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BITGF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 23, 2024 | $16.45 | $16.00 | -2.74% |
| Jul 16, 2024 | $16.14 | $17.38 | +7.68% |
| Apr 25, 2024 | $14.83 | $14.63 | -1.35% |
| Feb 15, 2024 | $14.17 | $16.18 | +14.18% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Biotage AB (BITGF) report earnings?
Biotage AB (BITGF) is schdueled to report earning on Feb 19, 2025, TBA Not Confirmed.
What is Biotage AB (BITGF) earnings time?
Biotage AB (BITGF) earnings time is at Feb 19, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BITGF EPS forecast?
BITGF EPS forecast for the fiscal quarter 2024 (Q4) is 0.14.
---